Overview
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide derived from Melanotan II. It is an agonist at melanocortin receptors MC1R, MC3R, MC4R, and MC5R. Unlike Melanotan II, bremelanotide was developed specifically for sexual dysfunction research after researchers noted that Melanotan II clinical trials produced spontaneous erections as a side effect, prompting investigation of the mechanism. Bremelanotide received FDA approval in 2019 under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women — making it one of the few peptides in this library with active FDA approval. It is administered as an intranasal spray or subcutaneous injection 45 minutes before anticipated sexual activity.
Mechanism
PT-141 activates MC4R (and to a lesser extent MC3R) in the central nervous system — particularly in the hypothalamus and limbic system — to produce pro-sexual effects. Unlike phosphodiesterase inhibitors (which act peripherally on blood vessels), bremelanotide works centrally on the neural circuits that generate sexual desire and arousal. It does not require sexual stimulation to be effective and works in both men and women in this respect.
Research Areas
Side Effects (Preclinical)
- – Nausea (most common; 40% in clinical trials)
- – Flushing
- – Headache
- – Transient blood pressure increase
- – Hyperpigmentation with repeated use
Cautions
- – For research use only — pharmaceutical Vyleesi (bremelanotide) is an approved drug
- – Cardiovascular disease: transient blood pressure elevation noted; avoid in uncontrolled hypertension
- – Hyperpigmentation risk with chronic use (MC1R activation)
Menopause & Women's Health Relevance
Hypoactive sexual desire disorder (HSDD) affects up to 40% of post-menopausal women. PT-141 (bremelanotide) is the only FDA-approved peptide specifically indicated for HSDD, working centrally via melanocortin receptors rather than peripherally — meaning it addresses desire, not just physical arousal. The RECONNECT trials enrolled both pre- and post-menopausal women.
What the research shows
PT-141’s FDA approval for HSDD in 2019 gives it a validated clinical dataset. The Phase III RECONNECT trials showed statistically significant improvements in satisfying sexual events and female sexual distress scale scores versus placebo in premenopausal women with HSDD.
The central (brain-mediated) mechanism is well-established and distinguishes it clearly from peripheral vasodilatory approaches like PDE5 inhibitors. This makes it an important research tool for melanocortin neuropharmacology beyond just sexual function.
References
- Bremelanotide for Hypoactive Sexual Desire Disorder — Simon JA et al. (2019)
- The melanocortin system and sexual function — Pfaus JG et al. (2007)